{"id":"NCT01680159","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2012-09-07","resultsPosted":"2017-03-13","lastUpdate":"2017-03-13"},"enrollment":51,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis","Psoriatic Arthritis","Pustular Psoriasis (Excluding a Localized)","Psoriatic Erythroderma"],"interventions":[{"type":"DRUG","name":"TA-650","otherNames":[]}],"arms":[{"label":"TA-650","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment with RemicadeÂ® at 5 mg/kg every 8 weeks but decreased thereafter.","primaryOutcome":{"measure":"Percentage of Patients Achieving 75% Improvement in the Psoriasis Area and Severity Index (PASI) Score","timeFrame":"Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 in Increased Dose Period","effectByArm":[{"arm":"Overall","deltaMin":0,"sd":null},{"arm":"Plaque Psoriasis","deltaMin":0,"sd":null},{"arm":"Psoriatic Arthritis","deltaMin":0,"sd":null},{"arm":"Pustular Psoriasis","deltaMin":0,"sd":null},{"arm":"Psoriatic Erythroderma","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["Double stranded DNA antibody positive","Nasopharyngitis","Headache","Urticaria","Vomiting"]}}